Seguir
Eduardo Diaz-Rubio
Eduardo Diaz-Rubio
Profesor Medicina. Universidad Complutense. Madrid
E-mail confirmado em salud.madrid.org
Título
Citado por
Citado por
Ano
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2013-2019, 2008
38982008
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
33912016
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous …
JB Vermorken, J Trigo, R Hitt, P Koralewski, E Diaz-Rubio, F Rolland, ...
Journal of clinical oncology 25 (16), 2171-2177, 2007
11322007
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2006-2012, 2008
10762008
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ...
The lancet oncology 15 (4), 406-414, 2014
9182014
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
J Cassidy, J Tabernero, C Twelves, R Brunet, C Butts, T Conroy, ...
Journal of Clinical Oncology 22 (11), 2084-2091, 2004
7232004
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the …
J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ...
The Lancet Oncology 17 (12), 1709-1719, 2016
4952016
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
D Machover, E Diaz-Rubio, A De Gramont, A Schilf, JJ Gastiaburu, ...
Annals of Oncology 7 (1), 95-98, 1996
4881996
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
J Tabernero, E Van Cutsem, E Díaz-Rubio, A Cervantes, Y Humblet, ...
Journal of clinical oncology 25 (33), 5225-5232, 2007
4012007
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final …
E Díaz-Rubio, J Tabernero, A Gómez-España, B Massutí, J Sastre, ...
Journal of Clinical Oncology 25 (27), 4224-4230, 2007
3552007
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
British journal of cancer 105 (1), 58-64, 2011
3102011
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study
E Diaz-Rubio, J Sastre, A Zaniboni, R Labianca, H Cortes-Funes, ...
Annals of Oncology 9 (1), 105-108, 1998
3081998
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables
J Sastre, ML Maestro, J Puente, S Veganzones, R Alfonso, S Rafael, ...
Annals of Oncology 19 (5), 935-938, 2008
2942008
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase …
E Díaz-Rubio, A Gómez-España, B Massutí, J Sastre, A Abad, ...
The oncologist 17 (1), 15-25, 2012
2722012
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis
FC Bidard, S Michiels, S Riethdorf, V Mueller, LJ Esserman, A Lucci, ...
JNCI: Journal of the National Cancer Institute 110 (6), 560-567, 2018
2582018
Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF …
M Martin, A Villar, A Sole-Calvo, R Gonzalez, B Massuti, J Lizon, ...
Annals of Oncology 14 (6), 833-842, 2003
2482003
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
M Cristofanilli, JY Pierga, J Reuben, A Rademaker, AA Davis, DJ Peeters, ...
Critical reviews in oncology/hematology 134, 39-45, 2019
2422019
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence …
C Twelves, W Scheithauer, J McKendrick, JF Seitz, G Van Hazel, A Wong, ...
Annals of oncology 23 (5), 1190-1197, 2012
2362012
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials
HT Arkenau, D Arnold, J Cassidy, E Diaz-Rubio, JY Douillard, H Hochster, ...
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2008
2312008
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
J Bellmunt, V Guillem, L Paz-Ares, JL Gonzalez-Larriba, J Carles, ...
Journal of clinical oncology 18 (18), 3247-3255, 2000
2242000
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20